New cancer drug enters human testing for Tough-to-Treat tumors
Disease control
Recruiting now
This early-stage study is testing a new drug called OBI-902 in people with advanced solid tumors that have stopped responding to standard treatments. Researchers will first find the safest dose, then test that dose in specific cancer types to see if it shows early signs of fighti…
Phase: PHASE1, PHASE2 • Sponsor: OBI Pharma, Inc • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC